Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
Más filtros

Medicinas Complementárias
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Int J Mol Sci ; 20(14)2019 Jul 17.
Artículo en Inglés | MEDLINE | ID: mdl-31319552

RESUMEN

Acne is an inflammatory skin disorder in puberty with symptoms including papules, folliculitis, and nodules. Propionibacterium acnes (P. acnes) is the main anaerobic bacteria that cause acne. It is known to proliferate within sebum-blocked skin hair follicles. P. acnes activates monocytic cell immune responses to induce the expression of proinflammatory cytokines. Although the anti-inflammatory function of the Laurus nobilis (L. nobilis) extract (LNE) on several immunological disorders have been reported, the effect of LNE in P. acnes-mediated skin inflammation has not yet been explored. In the present study, we examined the ability of the LNE to modulate the P. acnes-induced inflammatory signaling pathway, and evaluated its mechanism. LNE significantly suppressed the expression of P. acnes-mediated proinflammatory cytokines, such as IL-1ß, IL-6, and NLRP3. We also found that LNE inhibited the inflammatory transcription factor NF-κB in response to P. acnes. In addition, eucalyptol, which is the main constituent of LNE, consistently inhibited P. acnes-induced inflammatory signaling pathways. Moreover, LNE significantly ameliorated P. acnes-induced inflammation in a mouse model of acne. We suggest for the first time that LNE hold therapeutic value for the improvement of P. acnes-induced skin inflammation.


Asunto(s)
Acné Vulgar/tratamiento farmacológico , Antiinflamatorios/farmacología , Eucaliptol/farmacología , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Laurus/química , Extractos Vegetales/farmacología , Propionibacterium acnes/crecimiento & desarrollo , Acné Vulgar/metabolismo , Acné Vulgar/microbiología , Acné Vulgar/patología , Animales , Antiinflamatorios/química , Línea Celular , Eucaliptol/química , Infecciones por Bacterias Grampositivas/metabolismo , Infecciones por Bacterias Grampositivas/microbiología , Infecciones por Bacterias Grampositivas/patología , Inflamación/tratamiento farmacológico , Inflamación/metabolismo , Inflamación/microbiología , Inflamación/patología , Ratones , Extractos Vegetales/química
3.
Int. j. odontostomatol. (Print) ; 12(4): 355-361, dic. 2018. tab, graf
Artículo en Español | LILACS | ID: biblio-975757

RESUMEN

RESUMEN: El objetivo del estudio fue determinar el efecto antibacteriano in vitro de la oleorresina de Copaifera reticulata (C. reticulata) "copaiba" y del aceite esencial de Oreganum majoricum (O. majoricum) "orégano" frente a Streptococcus mutans (S. mutans) y Enterococcus faecalis (E. faecalis). Se desarrollaron pruebas de sensibilidad activando primero las cepas bacterias a enfrentar. La oleorresina de copaiba fue diluida con dimetilsulfósido (DMSO), obteniéndose al final concentraciones a probar de 100 %, 50 %, 25 %, y 12,5 %. En relación al aceite esencial de orégano este se probó solamente al 100 %. Para la prueba de difusión en agar con discos, se tomaron inóculos 100 µL de cada cepa bacteriana a una turbidez de 0,5 de Mc Farlam, para ser sembrados por diseminación en placas de tripticasa soya agar, para luego colocar los discos de forma equidistante cargados con las diferentes concentraciones de los productos naturales, se utilizaron como control positivo a la clorhexidina al 0,12 % y al DMSO como control negativo. Se incubaron las placas por el método de la vela en extinción a 37 °C, por un periodo de 24 horas, pasado el tiempo se realizó la lectura de los halos de inhibición. Los resultados obtenidos por la copaiba, determinaron un efecto antibacteriano en sus cuatro concentraciones, siendo los mayores halos de inhibición a la concentración del 100 %, copaiba genero mayores halos promedios para S, mutans de 30,00 ± 0,00 mm y para E. faecalis de 8,3 ± 0,50 mm. Para el caso del orégano se producen halos a la concentración del 100 % con un promedio de 25,3 ± 0,96 mm para S. mutans y para E. faecalis de 9,5 ± 1,29 mm. Se concluye del estudio que tanto copaiba como el orégano presentan un efecto antibacteriano para ambas bacterias, siendo su mayor efecto antibacteriano para ambos productos naturales sobre S. mutans.


ABSTRACT: The objective of the study was to determine the in vitro antibacterial effect of the oleoresin of Copaifera reticulata (C. reticulata) "copaiba" and of the essential oil of Oreganum majoricum (O. majoricum) "oregano" against Streptococcus mutans (S. mutans) and Enterococcus faecalis (E. faecalis). Sensitivity tests were developed by first activating the bacteria strains to be confronted. The oleoresin of copaiba was diluted with dimethylsulphoside (DMSO), obtaining final concentrations to be tested of 100 %, 50 %, 25 %, and 12.5 %. In relation to the essential oil of oregano, it was only 100 % tested. For the disk agar diffusion test, 100 mL of each bacterial strain was taken at a turbidity of 0.5 of Mc Farlam, to be planted by dissecting trypticase soy agar plates, and then placing the disks equidistantly loaded with the different concentrations of natural products; 0.12 % chlorhexidine was used as a positive control and DMSO as negative control. The plates were incubated by the candle method in extinction at 37 °C, for a period of 24 hours, after which time the inhibition halos were read. The results obtained by the copaiba, determined an antibacterial effect in its four concentrations, being the biggest halos of inhibition at the concentration of 100 %, copaiba genus higher average halos for S. mutans of 30.00 ± 0.00 mm and for E. faecalis of 8.3 ± 0.50 mm. In the case of oregano, haloes are produced at a concentration of 100 % with an average of 25.3 ± 0.96 mm for S. mutans and for E. faecalis 9.5 ± 1.29 mm. It is concluded from the study that both copaiba and oregano present an antibacterial effect for both bacteria, being its greater antibacterial effect for both natural products on S. mutans.


Asunto(s)
Humanos , Streptococcus mutans/fisiología , Extractos Vegetales/farmacología , Infecciones por Bacterias Grampositivas/microbiología , Infecciones por Bacterias Grampositivas/patología , Enterococcus faecalis/patogenicidad , Origanum/química , Perú , Streptococcus mutans/inmunología , Técnicas In Vitro , Aceites Volátiles/análisis , Antibacterianos
4.
Artículo en Inglés | MEDLINE | ID: mdl-29133566

RESUMEN

Iclaprim is a bacterial dihydrofolate reductase inhibitor that is currently being evaluated in two phase 3 trials for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Prior animal infection model studies suggest that the pharmacokinetic/pharmacodynamic (PK/PD) drivers for efficacy are area under the concentration-time curve from 0 to 24 h at steady state (AUC0-24ss), AUC/MIC, and time above the MIC during the dosing interval (T > MIC), while QTc prolongation was associated with the maximal concentration at steady state (Cmaxss) in a thorough QTc phase 1 study. Using PK data collected from 470 patients from the previously conducted phase 3 complicated skin and skin structure infection (cSSSI) trials, population PK modeling and Monte Carlo simulation (MCS) were used to identify a fixed iclaprim dosage regimen for the ongoing phase 3 ABSSSI studies that maximizes AUC0-24ss, AUC/MIC, and T > MIC while minimizing the probability of a Cmaxss of ≥800 ng/ml relative to the values for the previously employed cSSSI regimen of 0.8 mg/kg of body weight infused intravenously over 0.5 h every 12 h. The MCS analyses indicated that administration of 80 mg as a 2-h infusion every 12 h provides 28%, 28%, and 32% increases in AUC0-24ss, AUC/MIC, and T > MIC, respectively, compared to values for the 0.8-mg/kg cSSSI regimen, while decreasing the probability of a Cmaxss of ≥800 ng/ml, by 9%. Based on PK/PD analyses, 80 mg iclaprim administered over 2 h every 12 h was selected as the dosing scheme for subsequent phase 3 clinical trials.


Asunto(s)
Antibacterianos/farmacocinética , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Modelos Estadísticos , Infecciones Neumocócicas/tratamiento farmacológico , Pirimidinas/farmacocinética , Infecciones Cutáneas Estafilocócicas/tratamiento farmacológico , Adulto , Anciano , Antibacterianos/sangre , Antibacterianos/farmacología , Área Bajo la Curva , Método Doble Ciego , Esquema de Medicación , Cálculo de Dosificación de Drogas , Femenino , Infecciones por Bacterias Grampositivas/sangre , Infecciones por Bacterias Grampositivas/microbiología , Infecciones por Bacterias Grampositivas/patología , Humanos , Masculino , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Staphylococcus aureus Resistente a Meticilina/crecimiento & desarrollo , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Método de Montecarlo , Infecciones Neumocócicas/sangre , Infecciones Neumocócicas/microbiología , Infecciones Neumocócicas/patología , Pirimidinas/sangre , Pirimidinas/farmacología , Infecciones Cutáneas Estafilocócicas/sangre , Infecciones Cutáneas Estafilocócicas/microbiología , Infecciones Cutáneas Estafilocócicas/patología , Streptococcus pneumoniae/efectos de los fármacos , Streptococcus pneumoniae/crecimiento & desarrollo , Enterococos Resistentes a la Vancomicina/efectos de los fármacos , Enterococos Resistentes a la Vancomicina/crecimiento & desarrollo
5.
Platelets ; 28(6): 595-601, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28033029

RESUMEN

Platelets may play a role in the high risk for vascular complications in Gram-positive sepsis. We compared the platelet reactivity of 15 patients with Gram-positive sepsis, 17 with Gram-negative sepsis and 20 healthy controls using a whole blood flow cytometry-based assay. Patients with Gram-positive sepsis had the highest median fluorescence intensity (MFI) of the platelet membrane expression of P-selectin upon stimulation with high dose adenosine diphosphate (ADP; P = 0.002 vs. Gram-negative and P = 0.005 vs. control groups) and cross-linked collagen-related peptide (CRP-XL; P = 0.02 vs. Gram-negative and P = 0.0001 vs. control groups). The Gram-positive group also demonstrated significantly higher ADP-induced fibrinogen binding (P = 0.001), as wll as platelet-monocyte complex formation (P = 0.02), compared to the Gram-negative group and had the highest plasma levels of platelet factor 4, ß-thromboglobulin and soluble P-selectin. In contrast, thrombin-antithrombin complex and C-reactive protein levels were comparable in both patient groups. In conclusion, common Gram-positive pathogens induce platelet hyperreactivity, which may contribute to a higher risk for vascular complications.


Asunto(s)
Plaquetas/metabolismo , Infecciones por Bacterias Gramnegativas/sangre , Infecciones por Bacterias Grampositivas/sangre , Monocitos/metabolismo , Activación Plaquetaria , Sepsis/sangre , Adenosina Difosfato/farmacología , Adulto , Anciano , Anciano de 80 o más Años , Plaquetas/patología , Proteína C-Reactiva/metabolismo , Femenino , Infecciones por Bacterias Gramnegativas/patología , Infecciones por Bacterias Grampositivas/patología , Humanos , Masculino , Persona de Mediana Edad , Monocitos/patología , Selectina-P/sangre , Factor Plaquetario 4/sangre , Sepsis/patología , beta-Tromboglobulina/metabolismo
6.
Klin Khir ; (4): 47-9, 2016 Apr.
Artículo en Ucraniano | MEDLINE | ID: mdl-27434955

RESUMEN

In the pleural empyema (PE) treatment, not depending on introduction of multiple operative procedures and the medicinal preparations application, some issues remain unsolved, including the infection agents verification, the most rapid bronchial fistula elimination and the lung volume restoration. The EP infection agents spectrum, their sensitivity to preparations were revealed, as well as the enhanced rate of the methicillin-resistant stamms (MRSA) and the microorganisms associations verification. A reduction of the infection agents sensitivity towards "simple" antibacterial preparations was established, so the physicians, treating PE, must prescribe "hard" antibiotics, what enhances its cost.


Asunto(s)
Antibacterianos/uso terapéutico , Fístula Bronquial/tratamiento farmacológico , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Bacterias Gramnegativas/efectos de los fármacos , Bacterias Grampositivas/efectos de los fármacos , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Antibacterianos/clasificación , Antibacterianos/economía , Fístula Bronquial/etiología , Fístula Bronquial/microbiología , Empiema Pleural/tratamiento farmacológico , Empiema Pleural/microbiología , Empiema Pleural/patología , Empiema Pleural/cirugía , Bacterias Gramnegativas/crecimiento & desarrollo , Bacterias Gramnegativas/aislamiento & purificación , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Infecciones por Bacterias Gramnegativas/microbiología , Infecciones por Bacterias Gramnegativas/patología , Infecciones por Bacterias Gramnegativas/cirugía , Bacterias Grampositivas/crecimiento & desarrollo , Bacterias Grampositivas/aislamiento & purificación , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Infecciones por Bacterias Grampositivas/microbiología , Infecciones por Bacterias Grampositivas/patología , Infecciones por Bacterias Grampositivas/cirugía , Humanos , Mediciones del Volumen Pulmonar , Staphylococcus aureus Resistente a Meticilina/crecimiento & desarrollo , Staphylococcus aureus Resistente a Meticilina/aislamiento & purificación , Pruebas de Sensibilidad Microbiana , Cavidad Pleural/microbiología , Cavidad Pleural/patología , Cavidad Pleural/cirugía , Neumonectomía/efectos adversos , Estudios Retrospectivos , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estafilocócicas/microbiología , Infecciones Estafilocócicas/patología , Infecciones Estafilocócicas/cirugía
7.
Curr Eye Res ; 41(2): 232-9, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-25658242

RESUMEN

PURPOSE: To compare bactericidal activities of daptomycin (DAP) and vancomycin (VAN) in an experimental rabbit model of Enterococcus faecalis endophthalmitis. MATERIALS AND METHODS: The right vitreous cavities of 24 New Zealand rabbits were inoculated with 100 colony-forming units of E. faecalis; and after 24 h, rabbits were randomly divided into three groups. DAP group (n = 8, 0.2 mg/0.05 ml intravitreally), VAN group (n = 8, 1 mg/0.05 ml intravitreally) and balanced salt solution group (BSS, n = 8, 0.05 ml intravitreally). Clinical examination scores were recorded, and vitreous aspirates were obtained for microbiological analysis on days 0, 1, 2, 3 and 4. Rabbits were sacrificed, and the eyes were enucleated for histopathological assessment. RESULTS: There was no difference between the DAP, VAN and BSS groups in terms of the clinical grading of endophthalmitis 24 h after the inoculation. The bacterial counts were similar between the VAN and DAP groups except on day 1, where it was significantly lower than those in the VAN group (p = 0.003). On day 4, 62% of the eyes treated with DAP, and 50% of the eyes treated with VAN were sterilized. All of the eyes from the BSS group showed increasing bacterial growth from day 0 to day 4. There was no difference between the DAP and VAN groups in terms of the histopathological and clinical examination scores, while they were significantly lower than those in the BSS group. CONCLUSIONS: This study demonstrates evidence of the effectiveness of DAP for the treatment of experimental E. faecalis endophthalmitis.


Asunto(s)
Antibacterianos/uso terapéutico , Daptomicina/uso terapéutico , Endoftalmitis/tratamiento farmacológico , Enterococcus faecalis/aislamiento & purificación , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Vancomicina/uso terapéutico , Animales , Antibacterianos/administración & dosificación , Recuento de Colonia Microbiana , Daptomicina/administración & dosificación , Modelos Animales de Enfermedad , Endoftalmitis/microbiología , Endoftalmitis/patología , Infecciones Bacterianas del Ojo/microbiología , Infecciones Bacterianas del Ojo/patología , Infecciones por Bacterias Grampositivas/microbiología , Infecciones por Bacterias Grampositivas/patología , Inyecciones Intravítreas , Pruebas de Sensibilidad Microbiana , Soluciones Oftálmicas , Conejos , Vancomicina/administración & dosificación
8.
Antimicrob Agents Chemother ; 60(1): 239-44, 2016 01.
Artículo en Inglés | MEDLINE | ID: mdl-26482312

RESUMEN

Gram-positive bacterial infections are an important cause of morbidity and death among cancer patients, despite current therapy. In this case-control study, we evaluated the clinical outcomes and safety of telavancin in cancer patients with uncomplicated Gram-positive bloodstream infections (BSIs). Between March 2011 and May 2013, we enrolled cancer patients with uncomplicated Gram-positive BSIs to receive intravenous telavancin therapy for at least 14 days for Staphylococcus aureus and 7 days for other Gram-positive cocci. Patients with baseline creatinine clearance (CLCR) values of >50 ml/min received 10 mg/kg/day of telavancin, and those with CLCR values between 30 and 49 ml/min received 7.5 mg/kg/day. Patients were compared with a retrospective cohort of 39 historical patients with Gram-positive BSIs, matched for underlying malignancy, infecting organism, and neutropenia status, who had been treated with vancomycin. A total of 78 patients were analyzed, with 39 in each group. The most common pathogen causing BSIs was S. aureus (51%), followed by alpha-hemolytic streptococci (23%), Enterococcus spp. (15%), coagulase-negative staphylococci (8%), and beta-hemolytic streptococci (3%). Sixty-two percent of patients had hematological malignancies, and 38% had solid tumors; 51% of the patients were neutropenic. The overall response rate determined by clinical outcome and microbiological eradication at 72 h following the initiation of therapy, in the absence of relapse, deep-seated infections, and/or infection-related death, was better with telavancin than with vancomycin (86% versus 61%; P = 0.013). Rates of drug-related adverse events were similar in the two groups (telavancin, 31%; vancomycin, 23%; P = 0.79), with similar rates of renal adverse events. Telavancin may provide a useful alternative to standard vancomycin therapy for Gram-positive BSIs in cancer patients. (This study has been registered at ClinicalTrials.gov under registration no. NCT01321879.).


Asunto(s)
Aminoglicósidos/administración & dosificación , Antibacterianos/administración & dosificación , Bacteriemia/tratamiento farmacológico , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Neoplasias Hematológicas/tratamiento farmacológico , Neutropenia/tratamiento farmacológico , Lesión Renal Aguda/etiología , Lesión Renal Aguda/patología , Adulto , Anciano , Anciano de 80 o más Años , Aminoglicósidos/efectos adversos , Antibacterianos/efectos adversos , Bacteriemia/complicaciones , Bacteriemia/patología , Femenino , Infecciones por Bacterias Grampositivas/complicaciones , Infecciones por Bacterias Grampositivas/patología , Cocos Grampositivos/efectos de los fármacos , Cocos Grampositivos/crecimiento & desarrollo , Neoplasias Hematológicas/complicaciones , Neoplasias Hematológicas/patología , Humanos , Lipoglucopéptidos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Neutropenia/complicaciones , Neutropenia/patología , Proyectos Piloto , Recurrencia , Resultado del Tratamiento , Vancomicina/administración & dosificación , Vancomicina/efectos adversos
9.
J Endod ; 41(8): 1353-8, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25958178

RESUMEN

INTRODUCTION: The aim of this study was to evaluate the efficacy of carboxymethyl chitosan (CMCS) and chitosan nanoparticles (CNps) to inactivate bacteria and prevent biofilm formation at sealer-dentin interfaces. METHODS: The study was divided into 3 stages: first stage, the experiment was conducted to analyze the antibacterial properties of CMCS in different formulations against biofilms; second stage, direct-contact and membrane-restricted methods were used to evaluate the antibacterial properties of an epoxy resin (ThermaSeal Plus; Dentsply Tulsa Dental, Tulsa, OK) and calcium silicate (MTA Fillapex; Angelus SA, Londrina, PR, Brazil) based-sealers with or without CNps; and third stage, biofilm formation at the sealer dentin interfaces of root dentin treated with CMCS and filled with gutta-percha and CNp incorporated sealer were analyzed after 1- and 4-week aging periods. The samples were treated and filled as follows: (1) distilled water: unaltered sealer (control group), (2) CMCS: sealer+CNps (CMCS group), and (3) CMCS/rose bengal: sealer+CNps (CMCS/RB group). Enterococcus faecalis was used to infect all the samples. Microbiological and microscopic analyses were used to assess the antibacterial characteristics. RESULTS: CMCS-based treatments effectively killed bacteria adherent on root dentin (P < .05). The addition of CNps to ThermaSeal enhanced its antibacterial ability by direct-contact and membrane-restricted tests (P < .05). The CNp incorporation significantly increased the antibacterial efficacy of root canal sealers even after a 4-week aging time (P < .05). CONCLUSIONS: This study highlighted the ability of CMCS to disinfect root canal dentin and inhibit bacterial adhesion. CNps in root canal sealers are capable of maintaining their antibacterial activity even after prolonged aging.


Asunto(s)
Antibacterianos/administración & dosificación , Quitosano/análogos & derivados , Dentina/efectos de los fármacos , Nanopartículas , Fototerapia/métodos , Selladores de Fosas y Fisuras/uso terapéutico , Animales , Biopelículas/efectos de los fármacos , Compuestos de Calcio/uso terapéutico , Bovinos , Cavidad Pulpar/efectos de los fármacos , Cavidad Pulpar/patología , Cavidad Pulpar/fisiopatología , Dentina/patología , Dentina/fisiopatología , Enterococcus faecalis/efectos de los fármacos , Enterococcus faecalis/fisiología , Resinas Epoxi/uso terapéutico , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Infecciones por Bacterias Grampositivas/patología , Infecciones por Bacterias Grampositivas/fisiopatología , Pulpitis/tratamiento farmacológico , Pulpitis/patología , Pulpitis/fisiopatología , Rosa Bengala/uso terapéutico , Silicatos/uso terapéutico , Factores de Tiempo
10.
J Immunol Res ; 2015: 482863, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26783541

RESUMEN

Intracellular killing of bacteria is one of the fundamental mechanisms against invading pathogens. Impaired intracellular killing of bacteria by phagocytes may be the reason of chronic infections and may be caused by antibiotics or substances that can be produced by some bacteria. Therefore, it was of great practical importance to examine whether phage preparations may influence the process of phagocyte intracellular killing of bacteria. It may be important especially in the case of patients qualified for experimental phage therapy (approximately half of the patients with chronic bacterial infections have their immunity impaired). Our analysis included 51 patients with chronic Gram-negative and Gram-positive bacterial infections treated with phage preparations at the Phage Therapy Unit in Wroclaw. The aim of the study was to investigate the effect of experimental phage therapy on intracellular killing of bacteria by patients' peripheral blood monocytes and polymorphonuclear neutrophils. We observed that phage therapy does not reduce patients' phagocytes' ability to kill bacteria, and it does not affect the activity of phagocytes in patients with initially reduced ability to kill bacteria intracellularly. Our results suggest that experimental phage therapy has no significant adverse effects on the bactericidal properties of phagocytes, which confirms the safety of the therapy.


Asunto(s)
Bacteriófagos/química , Terapia Biológica/métodos , Infecciones por Bacterias Gramnegativas/terapia , Infecciones por Bacterias Grampositivas/terapia , Monocitos/inmunología , Neutrófilos/inmunología , Bacteriófagos/fisiología , Estudios de Casos y Controles , Bacterias Gramnegativas/inmunología , Bacterias Gramnegativas/virología , Infecciones por Bacterias Gramnegativas/inmunología , Infecciones por Bacterias Gramnegativas/microbiología , Infecciones por Bacterias Gramnegativas/patología , Bacterias Grampositivas/inmunología , Bacterias Grampositivas/virología , Infecciones por Bacterias Grampositivas/inmunología , Infecciones por Bacterias Grampositivas/microbiología , Infecciones por Bacterias Grampositivas/patología , Humanos , Monocitos/microbiología , Neutrófilos/microbiología , Seguridad del Paciente , Fagocitosis/inmunología , Cultivo Primario de Células , Resultado del Tratamiento
11.
J Med Microbiol ; 62(Pt 10): 1624-1627, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23764743

RESUMEN

We report prosthetic knee arthritis in a 55-year-old diabetic man due to Granulicatella adiacens, a micro-organism present in the oral flora, usually described in endocarditis but rarely in prosthesis joint infection. This patient had undergone a dental extraction without antibiotic prophylaxis one month before, and an aseptic loosening of the prosthesis had been diagnosed previously. If antimicrobial prophylaxis against infective endocarditis for dental procedures is well established, such an approach is still controversial for joint prosthesis and should be considered in some conditions.


Asunto(s)
Artritis/diagnóstico , Carnobacteriaceae/aislamiento & purificación , Infecciones por Bacterias Grampositivas/diagnóstico , Articulación de la Rodilla/patología , Infecciones Relacionadas con Prótesis/diagnóstico , Enfermedades Estomatognáticas/complicaciones , Artritis/microbiología , Artritis/patología , Técnicas Bacteriológicas , ADN Bacteriano/química , ADN Bacteriano/genética , ADN Ribosómico/química , ADN Ribosómico/genética , Complicaciones de la Diabetes , Infecciones por Bacterias Grampositivas/microbiología , Infecciones por Bacterias Grampositivas/patología , Humanos , Articulación de la Rodilla/diagnóstico por imagen , Articulación de la Rodilla/microbiología , Masculino , Microscopía , Persona de Mediana Edad , Datos de Secuencia Molecular , Infecciones Relacionadas con Prótesis/microbiología , Infecciones Relacionadas con Prótesis/patología , ARN Ribosómico 16S/genética , Radiografía , Análisis de Secuencia de ADN
12.
BMC Biol ; 11: 61, 2013 May 21.
Artículo en Inglés | MEDLINE | ID: mdl-23692866

RESUMEN

BACKGROUND: The intestinal mucus layer plays a key role in the maintenance of host-microbiota homeostasis. To document the crosstalk between the host and microbiota, we used gnotobiotic models to study the influence of two major commensal bacteria, Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii, on this intestinal mucus layer. B. thetaiotaomicron is known to use polysaccharides from mucus, but its effect on goblet cells has not been addressed so far. F. prausnitzii is of particular physiological importance because it can be considered as a sensor and a marker of human health. We determined whether B. thetaiotaomicron affected goblet cell differentiation, mucin synthesis and glycosylation in the colonic epithelium. We then investigated how F. prausnitzii influenced the colonic epithelial responses to B. thetaiotaomicron. RESULTS: B. thetaiotaomicron, an acetate producer, increased goblet cell differentiation, expression of mucus-related genes and the ratio of sialylated to sulfated mucins in mono-associated rats. B. thetaiotaomicron, therefore, stimulates the secretory lineage, favoring mucus production. When B. thetaiotaomicron was associated with F. prausnitzii, an acetate consumer and a butyrate producer, the effects on goblet cells and mucin glycosylation were diminished. F. prausnitzii, by attenuating the effects of B. thetaiotaomicron on mucus, may help the epithelium to maintain appropriate proportions of different cell types of the secretory lineage. Using a mucus-producing cell line, we showed that acetate up-regulated KLF4, a transcription factor involved in goblet cell differentiation. CONCLUSIONS: B. thetaiotaomicron and F. prausnitzii, which are metabolically complementary, modulate, in vivo, the intestinal mucus barrier by modifying goblet cells and mucin glycosylation. Our study reveals the importance of the balance between two main commensal bacteria in maintaining colonic epithelial homeostasis via their respective effects on mucus.


Asunto(s)
Bacteroides/fisiología , Colon/microbiología , Células Caliciformes/microbiología , Mucosa Intestinal/microbiología , Moco/metabolismo , Polisacáridos/biosíntesis , Ruminococcus/fisiología , Acetatos/metabolismo , Animales , Bacteroides/ultraestructura , Infecciones por Bacteroides/microbiología , Infecciones por Bacteroides/patología , Diferenciación Celular , Colon/metabolismo , Colon/patología , Modelos Animales de Enfermedad , Regulación de la Expresión Génica , Vida Libre de Gérmenes , Glicosilación , Células Caliciformes/metabolismo , Células Caliciformes/patología , Infecciones por Bacterias Grampositivas/microbiología , Infecciones por Bacterias Grampositivas/patología , Células HT29 , Interacciones Huésped-Patógeno/genética , Humanos , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patología , Factor 4 Similar a Kruppel , Moco/microbiología , Ratas , Transducción de Señal , Factores de Tiempo
13.
Mod Rheumatol ; 20(6): 627-31, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20617357

RESUMEN

The case of a patient who previously had permanent acupuncture needles placed in the knee joint and had been doing well, with no evidence of infection, but who eventually underwent a revision total knee arthroplasty due to acupuncture needle-associated prosthetic infection is presented. The microorganism responsible for the infection was Enterococcus faecalis, a bacterium which rarely causes infection following arthroplasty. This case should be highlighted to increase the awareness of healthcare providers to acupuncture-associated subclinical infection that may be exacerbated by surgical manipulation.


Asunto(s)
Terapia por Acupuntura/efectos adversos , Artroplastia de Reemplazo de Rodilla , Prótesis de la Rodilla/microbiología , Infecciones Relacionadas con Prótesis/etiología , Ampicilina/uso terapéutico , Antibacterianos/uso terapéutico , Quimioterapia Combinada , Enterococcus faecalis/aislamiento & purificación , Femenino , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Infecciones por Bacterias Grampositivas/microbiología , Infecciones por Bacterias Grampositivas/patología , Humanos , Articulación de la Rodilla/microbiología , Articulación de la Rodilla/patología , Articulación de la Rodilla/cirugía , Meropenem , Persona de Mediana Edad , Infecciones Relacionadas con Prótesis/patología , Reoperación , Sulbactam/uso terapéutico , Tienamicinas/uso terapéutico
15.
J Infect Chemother ; 14(5): 361-7, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18936889

RESUMEN

We report a case of fulminant septicemia with Bacillus cereus resistant to carbapenem. A 33-year-old man was suffering from febrile neutropenia (FN) on day 15 after the start of remission-induction therapy for biphenotypic acute leukemia under gut decontamination with polymyxin B and nystatin. Meropenem, a carbapenem, was administered according to the guideline for FN. Two days later (on day 17), he complained of severe abdominal pain, lost consciousness, went into sudden cardiopulmonary arrest, and died. Autopsy showed multiple spots of hemorrhage and necrosis caused by bacterial plaque in the brain, lungs, and liver. B. cereus was isolated from a blood sample obtained in the morning on day 17 and it was after his death that the isolated B. cereus was revealed to be resistant to carbapenem. B. cereus obtained from blood samples has been reported to be usually sensitive to carbapenem and also to vancomycin, new quinolones, and clindamycin. If B. cereus resistant to carbapem increases, our method of gut decontamination with polymyxin B and nystatin may have to be changed to one containing a new quinolone for the prevention of septicemia. Careful watching to determine whether B. cereus resistant to carbapem increases may be also important for empiric therapy, because carbapenem is often selected as the initial therapy for FN in patients with severe neutropenia.


Asunto(s)
Bacillus cereus/efectos de los fármacos , Bacteriemia/microbiología , Carbapenémicos/uso terapéutico , Leucemia Bifenotípica Aguda/complicaciones , Adulto , Antibacterianos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Bacillus cereus/aislamiento & purificación , Bacteriemia/complicaciones , Bacteriemia/diagnóstico , Bacteriemia/tratamiento farmacológico , Tronco Encefálico/microbiología , Tronco Encefálico/patología , Carbapenémicos/farmacología , Fiebre/tratamiento farmacológico , Infecciones por Bacterias Grampositivas/complicaciones , Infecciones por Bacterias Grampositivas/diagnóstico , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Infecciones por Bacterias Grampositivas/patología , Humanos , Leucemia Bifenotípica Aguda/diagnóstico , Leucemia Bifenotípica Aguda/tratamiento farmacológico , Hígado/microbiología , Hígado/ultraestructura , Pulmón/microbiología , Pulmón/ultraestructura , Masculino , Pruebas de Sensibilidad Microbiana , Neutropenia/tratamiento farmacológico , Inducción de Remisión , Resistencia betalactámica
17.
Proc Natl Acad Sci U S A ; 103(27): 10414-10419, 2006 Jul 05.
Artículo en Inglés | MEDLINE | ID: mdl-16801562

RESUMEN

The alarming increase of antibiotic-resistant bacterial pathogens points to the need for novel therapeutic approaches to combat infection. To discover novel antimicrobials, we devised a screen to identify compounds that promoted the survival of the model laboratory nematode Caenorhabditis elegans infected with the human opportunistic pathogen Enterococcus faecalis. E. faecalis colonizes the nematode intestinal tract, forming a persistent lethal infection. Infected nematodes were rescued by antibiotic treatment in a dose-dependent manner, and antibiotic treatment markedly reduced the number of bacteria colonizing the nematode intestine. To facilitate high throughput screening of compound libraries, we adapted a previously developed agar-based C. elegans-E. faecalis infection assay so that it could be carried out in liquid medium in standard 96-well microtiter plates. We used this simple infection system to screen 6,000 synthetic compounds and 1,136 natural product extracts. We identified 16 compounds and 9 extracts that promoted nematode survival. Some of the compounds and extracts inhibited E. faecalis growth in vitro, but, in contrast to traditional antibiotics, the in vivo effective dose of many of these compounds was significantly lower than the minimum inhibitory concentration needed to prevent the growth of E. faecalis in vitro. Moreover, many of the compounds and extracts had little or no affect on in vitro bacterial growth. Our findings indicate that the whole-animal C. elegans screen identifies not only traditional antibiotics, but also compounds that target bacterial virulence or stimulate host defense.


Asunto(s)
Antibacterianos/farmacología , Caenorhabditis elegans/efectos de los fármacos , Caenorhabditis elegans/microbiología , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos/métodos , Enterococcus faecalis/efectos de los fármacos , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Animales , Antibacterianos/análisis , Antibacterianos/química , Antibacterianos/uso terapéutico , Caenorhabditis elegans/genética , Caenorhabditis elegans/inmunología , Medios de Cultivo , Enterococcus faecalis/fisiología , Infecciones por Bacterias Grampositivas/genética , Infecciones por Bacterias Grampositivas/microbiología , Infecciones por Bacterias Grampositivas/patología , Estructura Molecular , Mutación/genética , Tasa de Supervivencia
18.
Medicine (Baltimore) ; 85(2): 86-94, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16609347

RESUMEN

Endocarditis is uncommon in patients with cancer. The characteristics of culture-positive (CPE) and culture-negative endocarditis (CNE) in high-risk cancer patients are not known; therefore we sought to evaluate the disease characteristics in patients with endocarditis at a comprehensive cancer center. We retrospectively reviewed the transthoracic (TTE) and transesophageal (TEE) echocardiograms obtained from 654 consecutive cancer patients in whom endocarditis was suspected between 1994 and 2004. Endocarditis was confirmed in 45 (7%) of 654 patients using modified Duke University criteria based on information obtained from hospital records and computerized data systems. In 21 (95%) of 22 cases, TEE examinations were diagnostic, and 16 (42%) of 38 patients with initially nondiagnostic TTE studies had the diagnosis confirmed by TEE study; this difference between diagnostic TEE and initial nondiagnostic TTE was significant (p < 0.0001). Among the 26 (58%) patients with CPE, Staphylococcus aureus (35%) was the most common organism isolated, followed by coagulase-negative Staphylococcus species (23%). Eighteen (78%) of 23 patients with a central venous catheter had CPE, whereas only 8 (36%) of 22 patients without a central venous catheter had CPE (odds ratio [OR], 6.3; 95% confidence interval [CI], 1.69-23.53; p < 0.006). Vegetations were larger in patients with CPE than in patients with CNE (median +/- standard deviation, 10 +/- 8.8 vs. 8.7 +/- 3.9 mm). Fifteen patients (58%) with CPE and 10 (53%) with CNE had embolic complications. We note that cutaneous and septic pulmonary emboli were more common in patients with CPE than in patients with CNE (31% vs. 11% and 15% vs. 0%, respectively), whereas embolic cerebrovascular and fatal embolic coronary events were more common in patients with CNE than in those with CPE (37% vs. 12% and 21% vs. 0%, respectively; p = 0.026). The 4-week endocarditis-attributable death rate did not differ significantly between the groups (CPE, 15% vs. CNE, 32%; p = 0.28). On stepwise multivariate regression analysis, patients with neutropenia (OR, 22.52; 95% CI, 2.25-225.48; p < 0.008) and those with embolic cerebrovascular events (OR, 17.07; 95% CI, 1.63-178.45; p < 0.01) had an increased probability of death due to endocarditis. The clinical spectrums of CPE and CNE differed in these patients with cancer. In patients with CNE, embolic cerebrovascular and fatal myocardial infarction were relatively common.


Asunto(s)
Endocarditis Bacteriana/complicaciones , Endocarditis/complicaciones , Infecciones por Bacterias Gramnegativas/complicaciones , Infecciones por Bacterias Grampositivas/complicaciones , Neoplasias/complicaciones , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Ecocardiografía , Ecocardiografía Transesofágica , Endocarditis/diagnóstico , Endocarditis Bacteriana/diagnóstico , Endocarditis Bacteriana/mortalidad , Endocarditis Bacteriana/patología , Femenino , Infecciones por Bacterias Gramnegativas/diagnóstico , Infecciones por Bacterias Gramnegativas/patología , Infecciones por Bacterias Grampositivas/diagnóstico , Infecciones por Bacterias Grampositivas/patología , Corazón/microbiología , Humanos , Embolia Intracraneal/diagnóstico , Embolia Intracraneal/etiología , Embolia Intracraneal/patología , Masculino , Persona de Mediana Edad , Análisis Multivariante , Infarto del Miocardio/diagnóstico , Infarto del Miocardio/etiología , Infarto del Miocardio/patología , Neoplasias/microbiología , Neoplasias/terapia , Embolia Pulmonar/diagnóstico , Embolia Pulmonar/etiología , Embolia Pulmonar/patología , Estudios Retrospectivos , Factores de Riesgo , Infecciones Estafilocócicas/complicaciones , Infecciones Estafilocócicas/diagnóstico , Infecciones Estafilocócicas/patología , Staphylococcus aureus/aislamiento & purificación , Tromboembolia/diagnóstico , Tromboembolia/etiología , Tromboembolia/patología
19.
J Tissue Viability ; 14(3): 97-101, 2004 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-15709356

RESUMEN

In the literature maggot therapy is discussed as a promising and potent form of debridement therapy. The number of maggots needed to debride a wound is estimated at 10 per cm2, and more in case of a higher percentage of necrosis or slough. In the authors' hospital, from March 1999 to May 2002, 16 patients were successfully treated with maggot therapy. The average maggot treatment time was 27 days, with an average of seven maggot changes. Most patients were treated for osteomyelitis, with trauma being the leading aetiological factor. In accordance with in-vitro findings, maggot therapy was found to be more effective in gram-positive infected wounds. Gram-negative bacteria are cultured more often after maggot treatment than before it (p=0.001). The opposite effect was found for gram-positive infected wounds (non-significant p=0.07). In vivo maggots seem to be less effective against gram-negative infected wounds. The authors believe that a higher number of maggots is needed not only for a larger wound or a wound with a higher percentage covered with slough, but also for a wound infected with gram-negative bacteria.


Asunto(s)
Desbridamiento/métodos , Infecciones por Bacterias Gramnegativas/terapia , Infecciones por Bacterias Grampositivas/terapia , Larva , Infección de Heridas/terapia , Adulto , Anciano , Anciano de 80 o más Años , Animales , Vendajes , Estudios de Cohortes , Femenino , Infecciones por Bacterias Gramnegativas/microbiología , Infecciones por Bacterias Gramnegativas/patología , Infecciones por Bacterias Grampositivas/microbiología , Infecciones por Bacterias Grampositivas/patología , Humanos , Control de Infecciones , Masculino , Persona de Mediana Edad , Necrosis , Osteomielitis/microbiología , Osteomielitis/patología , Osteomielitis/terapia , Estudios Retrospectivos , Cuidados de la Piel/instrumentación , Cuidados de la Piel/métodos , Cuidados de la Piel/enfermería , Factores de Tiempo , Resultado del Tratamiento , Cicatrización de Heridas , Infección de Heridas/microbiología , Infección de Heridas/patología
20.
J Vet Pharmacol Ther ; 26(3): 193-8, 2003 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12755903

RESUMEN

The efficacy of intramammary treatments containing procaine penicillin G alone (treatment A) or a combination of procaine penicillin G and neomycin (treatment B) was compared in treating clinical bovine mastitis caused by gram-positive bacteria susceptible in vitro to penicillin G. Both treatments were supplemented with a single intramuscular injection of procaine penicillin G on the first day of treatment. The study was carried out using a double blind design on commercial dairy farms in Southern Finland. A total of 56 quarters were treated with treatment A and 61 with treatment B. The cure rates for both treatments were equal, which suggests that the use of the penicillin G-aminoglycoside combination does not increase the efficacy of the treatment over that achieved by using penicillin G alone in bovine clinical mastitis caused by penicillin-susceptible, gram-positive bacteria.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Mastitis Bovina/tratamiento farmacológico , Neomicina/uso terapéutico , Penicilina G Procaína/uso terapéutico , Penicilinas/uso terapéutico , Animales , Antibacterianos/administración & dosificación , Antibacterianos/farmacología , Bovinos , Industria Lechera , Método Doble Ciego , Quimioterapia Combinada/administración & dosificación , Quimioterapia Combinada/farmacología , Quimioterapia Combinada/uso terapéutico , Femenino , Bacterias Grampositivas/efectos de los fármacos , Infecciones por Bacterias Grampositivas/microbiología , Infecciones por Bacterias Grampositivas/patología , Inyecciones/veterinaria , Mastitis Bovina/microbiología , Mastitis Bovina/patología , Pruebas de Sensibilidad Microbiana , Neomicina/administración & dosificación , Neomicina/farmacología , Penicilina G Procaína/administración & dosificación , Penicilina G Procaína/farmacología , Penicilinas/administración & dosificación , Penicilinas/farmacología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA